BioLine Rx Ltd
BLRX
Company Profile
Business description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Contact
2 HaMa’ayan Street
Modi’in7177871
ISRT: +972 86429100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,674.20 | 49.30 | -0.57% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,516.76 | 13.72 | -0.06% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,252.46 | 150.77 | -0.39% |
| NZX 50 Index | 12,520.09 | 48.96 | -0.39% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,461.30 | 44.20 | -0.52% |
| SSE Composite Index | 3,365.07 | 5.17 | 0.15% |